Glenmede Trust Co. NA Sells 5,143 Shares of Novo Nordisk A/S (NYSE:NVO)

Glenmede Trust Co. NA decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 295,430 shares of the company’s stock after selling 5,143 shares during the period. Glenmede Trust Co. NA’s holdings in Novo Nordisk A/S were worth $35,177,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. Natixis Advisors LLC lifted its position in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the period. Zions Bancorporation N.A. boosted its stake in Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after acquiring an additional 6,726 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Novo Nordisk A/S by 14.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after acquiring an additional 37,346 shares during the last quarter. Private Wealth Partners LLC raised its position in shares of Novo Nordisk A/S by 155.1% during the 3rd quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock valued at $3,953,000 after acquiring an additional 20,188 shares during the last quarter. Finally, Buckingham Capital Management Inc. bought a new position in shares of Novo Nordisk A/S in the 3rd quarter worth $3,874,000. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $106.12 on Thursday. The stock has a market capitalization of $476.22 billion, a PE ratio of 34.34, a P/E/G ratio of 1.35 and a beta of 0.42. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The firm has a fifty day simple moving average of $113.80 and a 200 day simple moving average of $128.33. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.